Login to your account
Don’t have an account?
Create a Free AccountEditor's Choice Archive
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management
Giant cell arteritis (GCA) – previously known as Horton's disease or temporal arteritis – is the most common vasculitis affecting people older than 50 years [1]. GCA is characterized by granulomatous inflammation affecting large- and medium- sized arteries, leading to acute and chronic damage [2]. Apart from the clear-cut association with older age, other factors such as genetic variants in the major histocompatibility complex region, particularly the human leukocyte antigen DRB1*04:04, have been described to be related to the development of GCA [3].Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors
In the last decade, immune checkpoint inhibitors (ICIs) have become a therapeutic tool of paramount importance when managing malignancies. ICIs currently represent the standard of care for several advanced cancers [1]. Despite their remarkable efficacy, these agents are associated with the onset of peculiar clinical manifestations called immune-related adverse events (irAEs) [2].Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
Immune checkpoint inhibitors (ICI) have been a major breakthrough in the treatment scenario of patients affected by solid cancers and haematological malignancies. First-line pembrolizumab, a programmed cell death -1 (PD-1) inhibitor, was recently shown to lead to a two-fold increase of overall survival rate in a subgroup of naïve non-small-cell lung cancer (NSCLC) patients when compared to chemotherapy [1]. However, ICI came together with the occurrence of unique clinical manifestations called immune-related adverse events (irAEs) [2,3].
Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
